Bio-Rad Laboratories (BIO) Cost of Revenue (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cost of Revenue data on file, last reported at $282.7 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 1.18% year-over-year to $282.7 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 5.45% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 4.69% from the prior year.
• Cost of Revenue for Q1 2026 stood at $282.7 million, down from $348.0 million in the prior quarter.
• Over the last five years, Cost of Revenue for BIO reached as high as $348.0 million in Q4 2025 and fell as low as $279.4 million in Q1 2025.
• Historically, Cost of Revenue has averaged $305.5 million across 5 years, with a median of $306.3 million in 2025.
• Across the five-year window, Cost of Revenue dropped 11.06% in 2024 and grew 8.08% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $333.2 million in 2022, then decreased by 5.51% to $314.8 million in 2023, then increased by 3.43% to $325.6 million in 2024, then advanced by 6.88% to $348.0 million in 2025, then retreated by 18.76% to $282.7 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $282.7 million in Q1 2026, $348.0 million in Q4 2025, and $309.6 million in Q3 2025.